{"id":"lhrha-or-surgical-castration","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Hot flashes"},{"rate":"50-90","effect":"Erectile dysfunction"},{"rate":"50-90","effect":"Decreased libido"},{"rate":"10-20","effect":"Gynecomastia"},{"rate":"20-40","effect":"Fatigue"},{"rate":"variable","effect":"Bone density loss / osteoporosis"},{"rate":"1-5","effect":"Cardiovascular events (LHRH agonist)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"LHRH (luteinizing hormone-releasing hormone) agonists work by initially stimulating, then downregulating LHRH receptors on pituitary gonadotroph cells, ultimately suppressing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, which leads to decreased testicular testosterone production. Surgical castration achieves androgen deprivation through direct removal of the testes, the primary source of testosterone. Both approaches achieve similar clinical endpoints of severe testosterone suppression for androgen-dependent diseases.","oneSentence":"LHRH agonists suppress testosterone production by desensitizing the pituitary gland, while surgical castration directly removes the testes to eliminate androgen production.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:49:28.006Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic prostate cancer"},{"name":"Locally advanced prostate cancer"}]},"trialDetails":[{"nctId":"NCT02446405","phase":"PHASE3","title":"Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sydney","startDate":"2014-03","conditions":"Prostatic Neoplasms","enrollment":1125}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1669,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"LHRHA or Surgical Castration","genericName":"LHRHA or Surgical Castration","companyName":"University of Sydney","companyId":"university-of-sydney","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LHRH agonists suppress testosterone production by desensitizing the pituitary gland, while surgical castration directly removes the testes to eliminate androgen production. Used for Metastatic prostate cancer, Locally advanced prostate cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}